JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB318943

Recombinant Human ALDR1 Protein

Be the first to review this product! Submit a review

|

(0 Publication)

Recombinant Human ALDR1 Protein is a Human Full Length protein, expressed in Escherichia coli, with >95%, 0.005 EU/µg endotoxin level, suitable for Mass Spec, SDS-PAGE.

View Alternative Names

ALDR1, ALR2, AKR1B1, Aldo-keto reductase family 1 member B1, Aldehyde reductase, Aldose reductase, AR

2 Images
Mass Spectrometry - Recombinant Human ALDR1 Protein (AB318943)
  • Mass Spec

Supplier Data

Mass Spectrometry - Recombinant Human ALDR1 Protein (AB318943)

Mass determination by ESI-TOF. Predicted MW is 35910 Da (+/- 10 Da by ESI-TOF). Observed MW is 35917.27 Da.

SDS-PAGE - Recombinant Human ALDR1 Protein (AB318943)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant Human ALDR1 Protein (AB318943)

SDS-PAGE analysis of ab318943 under reducing conditions for 2ug protein.

Key facts

Purity

>95% HPLC

Endotoxin level

0.005 EU/µg

Expression system

Escherichia coli

Tags

Tag free

Applications

SDS-PAGE, Mass Spec

applications

Biologically active

No

Mass Spectrometry

LC-MS/MS

Accession

P15121

Animal free

Yes

Carrier free

No

Species

Human

Storage buffer

pH: 8 Constituents: 10% Glycerol (glycerin, glycerine), 0.3002% Tris HCl, 0.0297% (R*,R*)-1,4-Dimercaptobutan-2,3-diol

storage-buffer

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "Mass Spec": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column
style
left-column

Sequence info

[{"sequence":"MASRLLLNNGAKMPILGLGTWKSPPGQVTEAVKVAIDVGYRHIDCAHVYQNENEVGVAIQEKLREQVVKREELFIVSKLWCTYHEKGLVKGACQKTLSDLKLDYLDLYLIHWPTGFKPGKEFFPLDESGNVVPSDTNILDTWAAMEELVDEGLVKAIGISNFNHLQVEMILNKPGLKYKPAVNQIECHPYLTQEKLIQYCQSKGIVVTAYSPLGSPDRPWAKPEDPSLLEDPRIKAIAAKHNKTTAQVLIRFPMQRNLVVIPKSVTPERIAENFKVFDFELSSQDMTTLLSYNRNWRVCALLSCTSHKDYPFHEEF","proteinLength":"Full Length","predictedMolecularWeight":"35.91 kDa","actualMolecularWeight":"35.91 kDa","aminoAcidEnd":0,"aminoAcidStart":0,"nature":"Recombinant","expressionSystem":null,"accessionNumber":"P15121","tags":[]}]
style
left-column

Properties and storage information

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-80°C
Appropriate long-term storage conditions
-80°C
False
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Aldose reductase also known as AR or ALR2 is an important enzyme in the polyol pathway. It has a molecular mass of about 36 kDa and reduces aldehydes including glucose to their corresponding alcohols. Aldose reductase is expressed widely in various tissues such as kidney lens and retina. The enzyme uses NADPH as a cofactor which is important for its catalytic activity.
Biological function summary

The main function of aldose reductase involves converting glucose to sorbitol a process particularly active under hyperglycemic conditions. It does not form a part of a larger complex but works individually to facilitate this conversion. Sorbitol the product of its enzymatic reaction eventually converts to fructose through the action of sorbitol dehydrogenase. This two-step conversion can contribute to cellular damage due to osmotic stress when sorbitol accumulates.

Pathways

Aldose reductase plays a central role in the polyol pathway. This pathway becomes highly relevant when blood glucose levels are elevated. During such conditions aldose reductase activity increases to convert excess glucose to sorbitol. This activity links it to other proteins like sorbitol dehydrogenase which completes the conversion to fructose.

Aldose reductase has strong connections to diabetic complications specifically diabetic neuropathy and retinopathy. The enzyme’s increased activity under high glucose conditions can lead to osmotic stress and tissue damage. Interactions with other proteins in the metabolic shift associated with diabetes such as sorbitol dehydrogenase underline its involvement. Aldose reductase inhibitors show potential in mitigating these adverse effects by reducing sorbitol accumulation.
style
left-column

Specifications

Form

Liquid

style
left-column

General info

Function

Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols. Displays enzymatic activity towards endogenous metabolites such as aromatic and aliphatic aldehydes, ketones, monosacharides, bile acids and xenobiotics substrates. Key enzyme in the polyol pathway, catalyzes reduction of glucose to sorbitol during hyperglycemia (PubMed : 1936586). Reduces steroids and their derivatives and prostaglandins. Displays low enzymatic activity toward all-trans-retinal, 9-cis-retinal, and 13-cis-retinal (PubMed : 12732097, PubMed : 19010934, PubMed : 8343525). Catalyzes the reduction of diverse phospholipid aldehydes such as 1-palmitoyl-2-(5-oxovaleroyl)-sn -glycero-3-phosphoethanolamin (POVPC) and related phospholipid aldehydes that are generated from the oxydation of phosphotidylcholine and phosphatdyleethanolamides (PubMed : 17381426). Plays a role in detoxifying dietary and lipid-derived unsaturated carbonyls, such as crotonaldehyde, 4-hydroxynonenal, trans-2-hexenal, trans-2,4-hexadienal and their glutathione-conjugates carbonyls (GS-carbonyls) (PubMed : 21329684).

Sequence similarities

Belongs to the aldo/keto reductase family.

style
left-column

Product protocols

style
left-column

Target data

Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols. Displays enzymatic activity towards endogenous metabolites such as aromatic and aliphatic aldehydes, ketones, monosacharides, bile acids and xenobiotics substrates. Key enzyme in the polyol pathway, catalyzes reduction of glucose to sorbitol during hyperglycemia (PubMed : 1936586). Reduces steroids and their derivatives and prostaglandins. Displays low enzymatic activity toward all-trans-retinal, 9-cis-retinal, and 13-cis-retinal (PubMed : 12732097, PubMed : 19010934, PubMed : 8343525). Catalyzes the reduction of diverse phospholipid aldehydes such as 1-palmitoyl-2-(5-oxovaleroyl)-sn -glycero-3-phosphoethanolamin (POVPC) and related phospholipid aldehydes that are generated from the oxydation of phosphotidylcholine and phosphatdyleethanolamides (PubMed : 17381426). Plays a role in detoxifying dietary and lipid-derived unsaturated carbonyls, such as crotonaldehyde, 4-hydroxynonenal, trans-2-hexenal, trans-2,4-hexadienal and their glutathione-conjugates carbonyls (GS-carbonyls) (PubMed : 21329684).
See full target information AKR1B1
style
left-column
style
left-column
style
right-column

Complementary Products

Proteins & Peptides

AB191946

Recombinant Human ketohexokinase protein

  • 0
  • 0
Proteins & Peptides

AB289740

Recombinant Human NADPH oxidase 4 protein

SDS-PAGE - Recombinant Human NADPH oxidase 4 protein (AB289740)

  • 0
  • 0
Primary Antibodies

AB316016

Anti-Aldose reductase antibody [EPR28780-7]

20ul selling size|BOND RX™ Validated|Recombinant|RabMAb

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Aldose reductase antibody [EPR28780-7] (AB316016)

  • 0
  • 0
Assay Kits

AB273276

Aldose Reductase Activity Kit (Colorimetric)

Functional Studies - Aldose Reductase Activity Kit (Colorimetric) (AB273276)

  • 0
  • 0

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com